These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 37100349

  • 21. Weekly 17 alpha-hydroxyprogesterone caproate to prevent preterm birth among women living with HIV: a randomised, double-blind, placebo-controlled trial.
    Price JT, Vwalika B, Freeman BL, Cole SR, Saha PT, Mbewe FM, Phiri WM, Peterson M, Muyangwa D, Sindano N, Mwape H, Smithmyer ME, Kasaro MP, Rouse DJ, Goldenberg RL, Chomba E, Stringer JSA.
    Lancet HIV; 2021 Oct; 8(10):e605-e613. PubMed ID: 34509197
    [Abstract] [Full Text] [Related]

  • 22. Adjuvant 17-hydroxyprogesterone caproate in women withultrasound-indicated cerclage: a systematic review and meta-analysis.
    Lichter KE, Sheffield J, Graham EM, Eke AC.
    J Matern Fetal Neonatal Med; 2020 Sep; 33(18):3177-3184. PubMed ID: 30626240
    [Abstract] [Full Text] [Related]

  • 23. Intramuscular progesterone in women with twins and a prior singleton spontaneous preterm birth.
    Ward A, Greenberg V, Valcarcel B, Boelig RC, Al-Kouatly HB, Berghella V.
    Am J Obstet Gynecol MFM; 2020 Aug; 2(3):100124. PubMed ID: 33345870
    [Abstract] [Full Text] [Related]

  • 24. 17 α-hydroxyprogesterone caproate (Makena®): a guide to its use in the prevention of preterm birth.
    Hines M, Lyseng-Williamson KA, Deeks ED.
    Clin Drug Investig; 2013 Mar; 33(3):223-7. PubMed ID: 23413110
    [Abstract] [Full Text] [Related]

  • 25. 17α-hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: a randomized controlled trial.
    Lim AC, Schuit E, Bloemenkamp K, Bernardus RE, Duvekot JJ, Erwich JJHM, van Eyck J, Groenwold RHH, Hasaart THM, Hummel P, Kars MM, Kwee A, van Oirschot CM, van Pampus MG, Papatsonis D, Porath MM, Spaanderman ME, Willekes C, Wilpshaar J, Mol BWJ, Bruinse HW.
    Obstet Gynecol; 2011 Sep; 118(3):513-520. PubMed ID: 21860279
    [Abstract] [Full Text] [Related]

  • 26. 17 alpha-hydroxyprogesterone caproate does not prolong pregnancy or reduce the rate of preterm birth in women at high risk for preterm delivery and a short cervix: a randomized controlled trial.
    Winer N, Bretelle F, Senat MV, Bohec C, Deruelle P, Perrotin F, Connan L, Vayssière C, Langer B, Capelle M, Azimi S, Porcher R, Rozenberg P, Groupe de Recherche en Obstétrique et Gynécologie.
    Am J Obstet Gynecol; 2015 Apr; 212(4):485.e1-485.e10. PubMed ID: 25448515
    [Abstract] [Full Text] [Related]

  • 27. Prevention of preterm birth with vaginal progesterone or 17-alpha-hydroxyprogesterone caproate: a critical examination of efficacy and safety.
    O'Brien JM, Lewis DF.
    Am J Obstet Gynecol; 2016 Jan; 214(1):45-56. PubMed ID: 26558340
    [Abstract] [Full Text] [Related]

  • 28. Association of 17α-Hydroxyprogesterone Caproate and Risk of Infection.
    Mainiero AD, Rouse DJ, Lopes V, Hughes BL.
    Obstet Gynecol; 2015 Jul; 126(1):103-8. PubMed ID: 26241262
    [Abstract] [Full Text] [Related]

  • 29. Comparison the efficacy of vaginal progesterone versus 17-alpha-hydroxyprogesterone caproate to prevent preterm birth in high-risk pregnant women undergo cerclage: a randomized clinical trial.
    Alavi A, Ranjbar A, Atighpoor F, Zare S.
    J Matern Fetal Neonatal Med; 2022 Dec; 35(25):7438-7444. PubMed ID: 34470137
    [Abstract] [Full Text] [Related]

  • 30. Racial and ethnic disparities in use of 17-alpha hydroxyprogesterone caproate for prevention of preterm birth.
    Yee LM, Liu LY, Sakowicz A, Bolden JR, Miller ES.
    Am J Obstet Gynecol; 2016 Mar; 214(3):374.e1-6. PubMed ID: 26829989
    [Abstract] [Full Text] [Related]

  • 31. Effectiveness of 17-α-hydroxyprogesterone caproate on preterm birth prevention in women with history-indicated cerclage.
    Mackeen AD, Rafael TJ, Zavodnick J, Berghella V.
    Am J Perinatol; 2013 Oct; 30(9):755-8. PubMed ID: 23341330
    [Abstract] [Full Text] [Related]

  • 32. Preventing recurrent preterm birth with 125 mg of 17-alpha-hydroxyprogesterone caproate.
    Fukuda T, Kyozuka H, Murata T, Yasuda S, Yamaguchi A, Fujimori K.
    J Obstet Gynaecol Res; 2021 Sep; 47(9):3119-3126. PubMed ID: 34219326
    [Abstract] [Full Text] [Related]

  • 33. Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery.
    Spong CY, Meis PJ, Thom EA, Sibai B, Dombrowski MP, Moawad AH, Hauth JC, Iams JD, Varner MW, Caritis SN, O'Sullivan MJ, Miodovnik M, Leveno KJ, Conway D, Wapner RJ, Carpenter M, Mercer B, Ramin SM, Thorp JM, Peaceman AM, Gabbe S, National Institute of Child Health and Human Development Maternal Fetal Medicine Units Network.
    Am J Obstet Gynecol; 2005 Sep; 193(3 Pt 2):1127-31. PubMed ID: 16157124
    [Abstract] [Full Text] [Related]

  • 34. Prevention of preterm birth in triplets using 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial.
    Caritis SN, Rouse DJ, Peaceman AM, Sciscione A, Momirova V, Spong CY, Iams JD, Wapner RJ, Varner M, Carpenter M, Lo J, Thorp J, Mercer BM, Sorokin Y, Harper M, Ramin S, Anderson G, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Maternal-Fetal Medicine Units Network (MFMU).
    Obstet Gynecol; 2009 Feb; 113(2 Pt 1):285-92. PubMed ID: 19155896
    [Abstract] [Full Text] [Related]

  • 35. The Effect of Intramuscular 17α-Hydroxyprogesterone in Women Screened for Shortened Cervical Length.
    Wood SL, Williams BN, Szychowski JM, Owen J.
    Am J Perinatol; 2020 Jun; 37(7):659-665. PubMed ID: 31756763
    [Abstract] [Full Text] [Related]

  • 36. The effect of omega-3 supplementation on pregnancy outcomes by smoking status.
    Kuper SG, Abramovici AR, Jauk VC, Harper LM, Biggio JR, Tita AT.
    Am J Obstet Gynecol; 2017 Oct; 217(4):476.e1-476.e6. PubMed ID: 28549983
    [Abstract] [Full Text] [Related]

  • 37. 17-alpha-hydroxyprogesterone caproate for the prevention of preterm birth in women with prior preterm birth and a short cervical length.
    Berghella V, Figueroa D, Szychowski JM, Owen J, Hankins GD, Iams JD, Sheffield JS, Perez-Delboy A, Wing DA, Guzman ER, Vaginal Ultrasound Trial Consortium.
    Am J Obstet Gynecol; 2010 Apr; 202(4):351.e1-6. PubMed ID: 20350641
    [Abstract] [Full Text] [Related]

  • 38. Second trimester cervical length and risk of preterm birth in women with twin gestations treated with 17-α hydroxyprogesterone caproate.
    Durnwald CP, Momirova V, Rouse DJ, Caritis SN, Peaceman AM, Sciscione A, Varner MW, Malone FD, Mercer BM, Thorp JM, Sorokin Y, Carpenter MW, Lo J, Ramin SM, Harper M, Spong CY, Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network.
    J Matern Fetal Neonatal Med; 2010 Dec; 23(12):1360-4. PubMed ID: 20441408
    [Abstract] [Full Text] [Related]

  • 39. Cerclage in singleton gestations with an extremely short cervix (≤10 mm) and no history of spontaneous preterm birth.
    Gulersen M, Bornstein E, Domney A, Blitz MJ, Rafael TJ, Li X, Krantz D, Rochelson B.
    Am J Obstet Gynecol MFM; 2021 Sep; 3(5):100430. PubMed ID: 34271252
    [Abstract] [Full Text] [Related]

  • 40. Cerclage for the prevention of preterm birth in high risk women receiving intramuscular 17-α-hydroxyprogesterone caproate.
    Szychowski JM, Berghella V, Owen J, Hankins G, Iams JD, Sheffield JS, Perez-Delboy A, Wing DA, Guzman ER, Vaginal Ultrasound Trial Consortium.
    J Matern Fetal Neonatal Med; 2012 Dec; 25(12):2686-9. PubMed ID: 22889234
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.